Phase 4 Eczema Trial, Recruiting (NCT05758532)

Phase 4 Eczema Trial, Recruiting NCT05758532 Sponsor: Laure Pittet, MD-PhD Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT05758532 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The child's parent or guardian must agree to take part and sign a consent form
The child must be 6 months old
The child must be generally healthy, with no significant medical conditions and no concerning findings from their health history or a physical check-up
The child must be up to date with their vaccinations for their age following the Swiss vaccination schedule, including having received at least 2 doses of a vaccine containing DTP (diphtheria, tetanus, and whooping cough)
The last vaccine the child received must have been given at least 2 weeks before joining the trial

Who may not be able to join:

The child has a reason they cannot receive the MMR (measles, mumps, and rubella) vaccine, including a weakened immune system (confirmed, suspected, or planned in the future)
The child has a known allergy to any ingredient in the MMR vaccine
The child has received a live vaccine (a vaccine made with a weakened live virus) in the 4 weeks before joining the trial
The parent or guardian does not want their child to be vaccinated
There is already a medical reason for the child to receive the MMR vaccine early, such as a measles outbreak, planned treatment that will weaken the immune system, or upcoming travel to an area with a high risk of measles
The child needs the MMRV vaccine (which also covers chickenpox) instead of MMR, for example due to severe eczema or the parent's preference
The parent or guardian is unable to follow the study procedures, for example due to language barriers, psychological difficulties, or other concerns
The family plans to move abroad or be away for a long period during the trial
Another child from the same multiple birth (e.g. twins) is already taking part in the trial
The child is currently unwell with a significant illness (though joining may be delayed until they recover) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Laure F Pittet, MD-PhD, University Hospitals of Geneva

Phone: +41 22 372 33 11

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05758532

Sponsor: Laure Pittet, MD-PhD

Phase: Phase 4

Status: Recruiting

Condition: Eczema

Trial contact: +41 22 372 33 11

More information: https://clinicaltrials.gov/study/NCT05758532

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The child's parent or guardian must agree to take part and sign a consent form
The child must be 6 months old
The child must be generally healthy, with no significant medical conditions and no concerning findings from their health history or a physical check-up
The child must be up to date with their vaccinations for their age following the Swiss vaccination schedule, including having received at least 2 doses of a vaccine containing DTP (diphtheria, tetanus, and whooping cough)
The last vaccine the child received must have been given at least 2 weeks before joining the trial

Who may not be able to join:

The child has a reason they cannot receive the MMR (measles, mumps, and rubella) vaccine, including a weakened immune system (confirmed, suspected, or planned in the future)
The child has a known allergy to any ingredient in the MMR vaccine
The child has received a live vaccine (a vaccine made with a weakened live virus) in the 4 weeks before joining the trial
The parent or guardian does not want their child to be vaccinated
There is already a medical reason for the child to receive the MMR vaccine early, such as a measles outbreak, planned treatment that will weaken the immune system, or upcoming travel to an area with a high risk of measles
The child needs the MMRV vaccine (which also covers chickenpox) instead of MMR, for example due to severe eczema or the parent's preference
The parent or guardian is unable to follow the study procedures, for example due to language barriers, psychological difficulties, or other concerns
The family plans to move abroad or be away for a long period during the trial
Another child from the same multiple birth (e.g. twins) is already taking part in the trial
The child is currently unwell with a significant illness (though joining may be delayed until they recover) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Laure Pittet, MD-PhD

Registry

ClinicalTrials.gov

Start date

17 March 2023

Est. completion

1 April 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Incidence of respiratory infection within the 3 months following randomisation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov